Viriom
Viriom Inc. is dedicated to developing effective, affordable treatments for diseases of global interest, focusing on infectious and malignant diseases such as blood-borne and respiratory viral diseases and solid tumors. Their mission is to broaden access to new therapies worldwide, including developed and developing countries.
Industries
Nr. of Employees
large (251-1000)
Viriom
1450 Research Blvd., Suite 110, Rockville, MD 20850
Patents
Substituted 3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, pharmaceutical composition, method for the production and use thereof
US-12091423-B2
View Details
Substituted 3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, pharmaceutical composition, method for the production and use thereof
US-12091423-B2
View DetailsProducts
Oral NNRTI therapy for HIV‑1 (daily regimen; market‑authorized in select countries)
A daily oral non‑nucleoside reverse transcriptase inhibitor for treatment of HIV‑1 that has completed clinical studies and obtained market authorization in certain regional markets.
Fixed‑dose combination tablet for HIV‑1 (FDC with NRTIs)
Once‑daily fixed‑dose combination tablet combining a NNRTI with nucleoside reverse transcriptase inhibitors to provide a complete regimen.
Monthly (or less frequent) nanosphere injectable antiviral formulation
Long‑acting injectable nanosphere formulation developed for once‑monthly or less frequent administration as part of combination therapy.
Long‑acting oral weekly formulation for treatment and prophylaxis
Oral extended‑release formulation intended for once‑weekly dosing for treatment or pre/post‑exposure prophylaxis.
Antiviral therapeutic candidates for respiratory viruses (clinical/preclinical)
Small‑molecule antiviral candidates and combinations targeting respiratory viruses including SARS‑CoV‑2 and influenza; includes agents that have progressed into early clinical testing.
Oncology small‑molecule HDAC inhibitor program (phase II)
Clinical development program for a selective oral pan‑HDAC inhibitor targeting platinum‑resistant ovarian cancer and other solid tumor indications.
Oral NNRTI therapy for HIV‑1 (daily regimen; market‑authorized in select countries)
A daily oral non‑nucleoside reverse transcriptase inhibitor for treatment of HIV‑1 that has completed clinical studies and obtained market authorization in certain regional markets.
Fixed‑dose combination tablet for HIV‑1 (FDC with NRTIs)
Once‑daily fixed‑dose combination tablet combining a NNRTI with nucleoside reverse transcriptase inhibitors to provide a complete regimen.
Monthly (or less frequent) nanosphere injectable antiviral formulation
Long‑acting injectable nanosphere formulation developed for once‑monthly or less frequent administration as part of combination therapy.
Long‑acting oral weekly formulation for treatment and prophylaxis
Oral extended‑release formulation intended for once‑weekly dosing for treatment or pre/post‑exposure prophylaxis.
Antiviral therapeutic candidates for respiratory viruses (clinical/preclinical)
Small‑molecule antiviral candidates and combinations targeting respiratory viruses including SARS‑CoV‑2 and influenza; includes agents that have progressed into early clinical testing.
Oncology small‑molecule HDAC inhibitor program (phase II)
Clinical development program for a selective oral pan‑HDAC inhibitor targeting platinum‑resistant ovarian cancer and other solid tumor indications.
Services
Negotiation and execution of licensing, co‑development, joint‑venture and commercialization agreements to enable regional registrations and market launches.
Preparation of regulatory submissions and coordination of authorization activities in multiple jurisdictions.
Negotiation and execution of licensing, co‑development, joint‑venture and commercialization agreements to enable regional registrations and market launches.
Preparation of regulatory submissions and coordination of authorization activities in multiple jurisdictions.
Expertise Areas
- Clinical trial management
- Long‑acting formulation development
- Antiviral drug development and combination therapies
- Fixed‑dose combination development
Key Technologies
- Long‑acting injectable nanoformulations
- Nanosphere nanoparticle delivery
- Extended‑release oral (weekly) formulations
- Fixed‑dose combination tablets/capsules
News & Updates
Viriom Inc. announced the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus replication.
A comparison of the risk/benefit profiles of three leading oral antiviral drugs: Favipiravir, Molnupiravir, and Paxlovid.
Avifavir, the first direct oral antiviral drug, was registered in Indonesia based on data from a phase II-III clinical trial involving 460 patients.
Viriom Inc. announced the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus replication.
A comparison of the risk/benefit profiles of three leading oral antiviral drugs: Favipiravir, Molnupiravir, and Paxlovid.
Avifavir, the first direct oral antiviral drug, was registered in Indonesia based on data from a phase II-III clinical trial involving 460 patients.